Observational study for treatment outcome in patients with HER2-positive metastatic breast cancer who received pertuzumab combination chemotherapy.

Observational study for treatment outcome in patients with HER2-positive metastatic breast cancer who received pertuzumab combination chemotherapy. - Observational study for treatment outcome in patients with HER2-positive metastatic breast cancer who received pertuzumab combination chemotherapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012210

Enrollment

100

Registered

2013-11-05

Start date

2013-11-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Histologically confirmed breast cancer. 2) HER2-positive(3+ staining by IHC or HER2 gene amplification by FISH) metastatic breast cancer. 3) Received pertuzumab combination chemotherapy after September 12, 2013. 4) Written informed consent to participate.

Exclusion criteria

Exclusion criteria: 1) Physician judged improper to entry this trial

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Response rate Progression-free survival Overall survival Time to treatment failure The incidence of the adverse event (such as infusion reaction and decreasing of LVEF) Treatment line Treatment regimen	—

Countries

Japan

Contacts

Public ContactKeisuke Miwa

Kurume University Hospital Cancer Multidisciplinary Treatment Center

miwakeisuke@gmail.com0942-35-3311

Outcome results